Department of Pathology, University of Chicago, Chicago, IL, USA; Department of Surgery (Urology), University of Chicago, Chicago, IL, USA.
Department of Medicine (Hematology/Oncology), University of Chicago, Chicago, IL, USA.
Eur Urol. 2018 Apr;73(4):560-569. doi: 10.1016/j.eururo.2017.12.018. Epub 2018 Jan 9.
The Tumor-Node-Metastasis (TNM) classification on cancer staging, jointly developed by the American Joint Commission on Cancer (AJCC) and the Union for International Cancer Control (UICC), has been updated to its 8th edition with two contemporaneous versions published by the AJCC and UICC. While the goal of the AJCC and UICC is to have identical TNM staging systems, differences exist between these two publications including in the staging of urologic cancers. Among several new facets in the AJCC staging manual, a select few of greater import include an expanded section on imaging, presentation of levels of evidence for significant changes, and endorsement of risk assessment models that pass the AJCC quality criteria such as in prostate cancer. The updates for urologic cancers in the AJCC stage categories can be grouped into: (1) newly defined TNM categories and prognostic stage groupings, (2) clarifications and refinements of previously defined categories, and (3) more systematic and expanded presentation of prognostic factors. Changes are harmonized with the current reporting and treatment guidelines. Contributions from genitourinary pathology are evident in the AJCC classification from many of the International Society of Urological Pathology (ISUP) consensus conferences on prostate, kidney, testicular, and penile neoplasms that addressed staging issues and the timely publication of the 4th edition of the World Health Organization (WHO) classification of urinary and male genital organ tumors. New grading approaches for penile (WHO/ISUP grade), prostate (Grade group), and kidney (WHO/ISUP nucleolar grade) cancers were adopted in the AJCC system. Many of these updates in the AJCC staging manual are also included in the 8th UICC TNM edition. In an effort to achieve the optimal staging recommendations for urologic cancers, updates in the 8th TNM edition were generated through the acquisition of best evidences, tapping interdisciplinary resources including consensus recommendations, and enhanced data analysis.
In this report, we explain the seminal changes in the 8th edition of the Tumor-Node-Metastasis staging system for urologic cancers. Major stage category definitional changes are in Tumor-Node-Metastasis classifications of testicular, penile, and prostate cancer which improve patient stratification for prognosis and management.
癌症分期的肿瘤-淋巴结-转移(TNM)分类由美国癌症联合委员会(AJCC)和国际癌症控制联盟(UICC)联合制定,已更新至第 8 版,AJCC 和 UICC 同时发布了两个版本。虽然 AJCC 和 UICC 的目标是制定完全相同的 TNM 分期系统,但这两个版本之间存在差异,包括泌尿系统癌症的分期。在 AJCC 分期手册的几个新方面中,有几个更重要的方面包括扩展了影像学部分、展示了重大变化的证据水平,并认可了通过 AJCC 质量标准的风险评估模型,例如前列腺癌。AJCC 分期类别中泌尿系统癌症的更新可分为:(1)新定义的 TNM 类别和预后分期分组;(2)对先前定义类别的澄清和细化;(3)更系统和扩展的预后因素呈现。这些变化与当前的报告和治疗指南保持一致。泌尿生殖病理学的贡献在 AJCC 分类中显而易见,这是因为国际泌尿病理学会(ISUP)就前列腺、肾脏、睾丸和阴茎肿瘤的分期问题举行了多次共识会议,并及时出版了第 4 版世界卫生组织(WHO)泌尿系统和男性生殖器官肿瘤分类。AJCC 系统采用了阴茎(WHO/ISUP 分级)、前列腺(分级组)和肾脏(WHO/ISUP 核仁分级)癌症的新分级方法。AJCC 分期手册中的许多更新也包含在第 8 版 UICC TNM 中。为了为泌尿系统癌症制定最佳分期建议,第 8 版 TNM 中的更新是通过获取最佳证据、利用包括共识建议在内的跨学科资源以及增强数据分析来实现的。
在本报告中,我们解释了泌尿系统癌症第 8 版肿瘤-淋巴结-转移(TNM)分期系统的重大变化。肿瘤-淋巴结-转移分类中睾丸癌、阴茎癌和前列腺癌的主要分期类别定义性变化,提高了患者预后和管理的分层。